Zoetis (ZTS) Beats Earnings, Revenue Estimates In Q1
Zacks Investment Research | May 04, 2017 02:56AM ET
Zoetis Inc. (NYSE:ZTS) first-quarter 2017 earnings of 53 cents per share increased 10% year over year and surpassed the Zacks Consensus Estimate of 48 cents.
Total revenue growth was up 6% operationally (excluding the impact of currecy) to $1.23 billion year over year in the quarter and beat the Zacks Consensus Estimate of $1.19 billion.
In fact, a look at Zoetis’ share price movement year to date shows that the stock has underperformed the Zacks classified Medical-Drugs industry. The stock was up 3.8% compared with the industry’s gain of 4.2%.
Quarterly Highlights
Zoetis manages its business across two regional operating segments – the U.S. and International. Within these segments, the company offers a diverse portfolio of products for livestock and companion animals.
Revenues in the U.S. segment were up 4% to $631 million. Within this segment, sales of companion animal products were up 10%, reflecting higher sales of Apoquel and other product launches (Simparica Chewables and Cytopoint). However, Livestock revenues slipped 3% mainly due to decreased sales of swine and cattle products.
Revenues at the International segment grew 8% (up 9% operationally) on a reported basis to $615 million on a reported basis. Sales of livestock products were up 7% on a reported and operational basis in the quarter due to increased sales of swine products in China and Vietnam, and cattle products in Brazil. Nonetheless, livestock sales were adversely impacted by product rationalizations.
Sales of companion animal products grew 13% on a reported basis (up 15% operationally), driven by higher sales of Apoquel, new product launches, particularly Simparica and increased demand in China for the companion animal vaccines portfolio.
2017 Outlook
Zoetis reiterated its outlook for 2017. The company expects earnings in the range of $2.26 to $2.36 per share on revenues in $5.10 billion and $5.225 billion band. The Zacks Consensus Estimate for earnings is $2.67 per share on revenues of $5.49 billion.
Other Updates
The company received approval for Cytopoint in the European Union in Apr 2017 and in Canada in Mar 2017. The approval will help the company to strengthen its canine dermatology portfolio. In fact, Cytopoint is the first monoclonal antibody (mAb) therapy approved to help provide a reduction in the clinical signs associated with atopic dermatitis such as itching in dogs.
Get The News You Want
Also, Zoetis received European Commission approval for Stronghold Plus in Feb 2017. It is a topical combination product that treats ticks, fleas, ear mites, lice and gastrointestinal worms and prevents heartworm disease in cats.
During the quarter the company inked a deal to purchase Nexvet Biopharma plc, as well. The latter is an innovator in monoclonal antibody therapies for companion animals used in managing chronic pain as well as in other therapeutic areas.
Our Take
Zoetis’ first-quarter results were better than expected, with the company surpassing bottom-line estimates along with revenues. Performance of the companion animal business was encouraging due to higher global sales of Apoquel and other new products. The company maintained its outlook for 2017.
Notably, successful launches of new products and the diversity of the company’s portfolio boosted performance in the quarter. However, unfavorable currency movement continued to hurt the top line.
Zacks Rank & Stocks to Consider
Zoetis is a Zacks Rank #3 (Hold) stock. Top-ranked stocks in the health care sector include Aeglea BioTherapeutics (NASDAQ:AGLE) , Galena Biopharma, Inc. (NASDAQ:GALE) and Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) sporting a Zacks Rank #1 (Strong Buy). You can see .
Aeglea BioTherapeutics’ loss per share estimates narrowed from $3.64 to $2.48 for 2017 over the last 60 days. Its share price increased 52.8% year to date.
Galena’s loss per share estimates narrowed from $2.03 to 58 cents for 2017 over the last 60 days. The company posted positive earnings surprises in two of the four trailing quarters, with an average beat of 53.83%.
Infinity Pharma’s loss per share estimates narrowed from $1.43 to $1.03 for 2017 and from $1.75 to $1.52 over the last 60 days. The company posted positive earnings surprises in three of the four trailing quarters, with an average beat of 36.64%.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.